BRITO DE LA FUENTE, Edmundo,GALLEGOS-MONTES, Crispulo,QUINCHIA-BUSTAMENTE, Lida A.
申请号：
EPEP2015/051657
公开号：
WO2015/113987A1
申请日:
2015.01.28
申请国别(地区):
EP
年份:
2015
代理人:
摘要：
The present invention relates to a composition for parenteral administration comprising an aqueous phase and 5 to 30 % by weight of an oil phase, based on the total weight of the composition, wherein the oil phase comprises omega-3 fatty acid triglycerides selected from the group consisting of eicosapentaenoic acid triglycerides, docosahexaenoic acid triglycerides and mixtures thereof, and wherein the composition further comprises at least one amphoteric surfactant, at least one co-surfactant and at least one co-solvent, and wherein the composition comprises less than 0.03 % by weight of sodium oleate, based on the total weight of the composition. Further, the present invention relates to a method for preparing such a composition as well as to such a composition for use as a medicament, in particular for use in treating stroke, sepsis, Alzheimer's disease or cancer. Furthermore, the present invention relates to a method for treating stroke, sepsis, Alzheimer's disease or cancer comprising parenterally administering such a composition to a patient in need thereof and to a method of providing parenteral nutrition to a patient suffering from at least one disease selected from stroke, sepsis, Alzheimer's disease or cancer, the method comprising administering such a composition to the patient.La présente invention concerne une composition pour administration parentérale comprenant une phase aqueuse et 5 à 30 % en poids d'une phase huileuse, sur la base du poids total de la composition, la phase huileuse comprenant des triglycérides d'acide gras oméga 3 sélectionnés à partir du groupe constitué de triglycérides d'acide eicosapentaénoïque, de triglycérides d'acide docosahexaénoïque et de leurs mélanges, et la composition comprenant en outre au moins un surfactant amphotère, au moins un co-surfactant et au moins un co-solvant, et la composition comprenant moins de 0,03 % en poids d'oléate de sodium, sur la base du poids total de la composition. De plus, la présente inventio
